<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60585">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02155335</url>
  </required_header>
  <id_info>
    <org_study_id>8259-027</org_study_id>
    <secondary_id>2014-000656-29</secondary_id>
    <nct_id>NCT02155335</nct_id>
  </id_info>
  <brief_title>Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)</brief_title>
  <acronym>SMART</acronym>
  <official_title>Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine whether ulcerative colitis participants prefer delivery
      of golimumab via a prefilled syringe or the Smartject™ device.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants Who Prefer Prefilled Syringe, Smartject™ Device, or are Undecided</measure>
    <time_frame>Up to Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Golimumab Prefilled Syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Golimumab 50 mg supplied in a prefilled syringe administered four times (two times by the treating physician and 2 times by the participant under the supervision of the treating physician).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Golimumab Smartject™ Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Golimumab 50 mg supplied in an auto-injector device administered four times (two times bythe treating physician and 2 times by the participant under the supervision of the treating physician).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab Prefilled Syringe</intervention_name>
    <description>Golimumab 50 mg via subcutaneous injection.</description>
    <arm_group_label>Golimumab Prefilled Syringe</arm_group_label>
    <other_name>SIMPONI</other_name>
    <other_name>MK-8259-027</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab Smartject™ Device</intervention_name>
    <description>Golimumab 50 mg via subcutaneous injection.</description>
    <arm_group_label>Golimumab Smartject™ Device</arm_group_label>
    <other_name>SIMPONI</other_name>
    <other_name>MK-8259-027</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anti-tumor necrosis factor (anti-TNF) naive participants with a diagnosis of
             moderate-to-severe ulcerative colitis.

          -  Mayo clinic score &gt;= 6, including endoscopic subscore &gt;=2;

          -  Previous conventional therapy for a period of at least 3 months with aminosalicylates
             and at least 3 months with corticosteroids or  6-mercaptopurine (6-MP) or
             azathioprine (AZA), unless the participant is intolerant to, or has contraindications
             to these treatments;

          -  Anti-TNF experienced participants with an established diagnosis of moderate-to-severe
             ulcerative colitis, either not responding or partially responding to treatment with
             Remicade (infliximab). The participant must also meet the following criteria prior to
             initiating first-line anti-TNF treatment: Mayo score ≥ 6, including an endoscopic
             subscore ≥ 2; and previous conventional therapy of at least 3 months with
             aminosalicylates and at least 3 months with corticosteroids or 6-mercaptopurine
             (6-MP) or azathioprine (AZA), unless the participant is intolerant to or have medical
             contraindications for such therapies (should be documented);

          -  Sexually active women of child-bearing potential must agree to use a medically
             accepted method of contraception while receiving study drug and for 6 months after
             the stop of study drug;

        Exclusion Criteria:

          -  Has a history of prior self-injection for any reason;

          -  Has concomitant use of other biologic agents;

          -  Has active tuberculosis (TB) within 12 months prior to the first injection or  has
             suspected latent TB as indicated by a positive tuberculin skin test.

          -  Has an active clinical non-tuberculous mycobacterial infection or opportunistic
             infection within 6 months prior to the first injection;

          -  Has had an active infection and/or serious infection within 6 months prior to the
             first study drug administration;

          -  Has had a live viral or bacterial vaccination within 3 months prior to the first
             study injection or Bacillus Calmette-Guerin vaccination within 12 months prior to the
             first study drug injection;

          -  Has evidence of heart failure of New York Heart Association class 3-4;

          -  Has a history of demyelinating disease such as multiple sclerosis or optic neuritis;

          -  Has a history of systemic lupus erythematosus;

          -  Has a history of lymphoproliferative disease, or any unknown malignancy or history of
             malignancy within the prior 5 years, with the exception of non-melanoma skin cancer
             that has been treated with no evidence of recurrence;

          -  Has had an active hepatitis B infection;

          -  Has an allergy or sensitivity to golimumab or its excipients;

          -  Is pregnant or breast feeding;

          -  Is sensitive to latex.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll-Free Number</last_name>
    <phone>888-577-8839</phone>
    <email>ClinicalTrialsDisclosure@merck.com</email>
  </overall_contact>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>June 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
